CamDiab’s automated insulin delivery technology gets regulatory progress toward fully closed-loop systems and continued international expansion of the CamAPS FX platform.
Image courtesy of CamDiab Ltd
Algorithm innovation
In January, CamDiab announced that its latest automated insulin delivery algorithm received CE marking in Europe. The update enables a fully closed-loop system, meaning insulin delivery can be automated without the need for carbohydrate counting or pre-meal insulin boluses.
The system uses continuous glucose data to adjust insulin delivery automatically through a compatible pump and smartphone app. CamDiab said the technology aims to reduce the daily burden of diabetes management by allowing the algorithm to handle insulin adjustments without frequent user input.
A pilot rollout of the fully closed-loop algorithm is expected to begin during 2026, with broader availability planned afterwards.
UK context
CamDiab’s technology has strong links to the UK. The CamAPS FX algorithm was developed from research led by Professor Roman Hovorka at the University of Cambridge and is already used within hybrid-closed loop systems by many people with type 1 diabetes.
The system runs through a smartphone app that connects a compatible insulin pump with a CGM sensor to automate insulin delivery. It can operate with sensors including FreeStyle Libre 3 and Dexcom G6.
Because CamAPS FX already supports widely used CGM systems, the move toward a fully closed-loop algorithm could be particularly relevant for people using hybrid-closed loop systems within the NHS.
International developments
CamAPS FX is already available across multiple countries and continues to expand internationally. The platform is currently used in more than a dozen countries in Europe and has been cleared for use in additional markets including the United States and Canada.
The system typically operates with the mylife YpsoPump insulin pump, and the combination has already been deployed in Europe as part of hybrid-closed loop therapy programmes.
CamDiab’s algorithm has also been used in partnership with other diabetes technology companies. For example, Abbott’s FreeStyle Libre sensors have been integrated into automated insulin delivery systems using CamDiab’s algorithm in Europe.
What this means
The approval of a fully closed-loop algorithm represents an important step toward systems that automate insulin delivery without requiring users to calculate carbohydrates or deliver meal boluses.
__________
Disclaimer
Blogs and publications on this website are independent of any involvement by medtech companies or diabetes related charities. To ensure there is no bias, we do not accept any products, freebies or other material from any medtech provider. Except where credited otherwise, all materials are copyright ©️Love My Libre Ltd.
What CGM is not associated or affiliated with Abbott or FreeStyle Libre. Content here and on our website what cgm.com does not constitute medical advice or replace the relationship between you and healthcare professionals nor the advice you receive from them.
The author of this blog has type 1 diabetes and uses a CGM on NHS prescription.
Leave a comment (all fields required). Please note, we are unable to respond to individual comments posted here.